AZR stock news today

Azora Therapeutics posts Q3 2026 results and business update

Azora Therapeutics issued its quarterly financial figures for the period ended in 2026 and shared a status update on its operations. No specific numbers were given in the headline.

Form 8-K tells shareholders about important events such as deals, leadership changes or results.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

Jones Trading starts Azora Therapeutics coverage with Buy rating and $14 price target

Jones Trading began covering Azora Therapeutics with a Buy rating and set a $14 price target on the shares.

Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.

What is the latest news on AZR?

Nov 13, 2026: Azora Therapeutics posts Q3 2026 results and business update (Fiscal.ai) · Nov 9, 2026: Adial Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K) (SEC) · Nov 3, 2026: Adial Pharmaceuticals, Inc. filed an insider trading report (Form 4) (SEC)

What has AZR filed with the SEC recently?

Nov 9, 2026: Adial Pharmaceuticals, Inc. filed a report on a major company event (Form 8-K) · Nov 3, 2026: Adial Pharmaceuticals, Inc. filed an insider trading report (Form 4) · Oct 30, 2026: Adial Pharmaceuticals, Inc. filed an insider trading report (Form 4)